PACS Group (NYSE:PACS – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Profitability
This table compares PACS Group and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PACS Group | 3.62% | 22.55% | 3.45% |
| Aclarion | -9,517.11% | -52.31% | -49.79% |
Insider and Institutional Ownership
7.5% of Aclarion shares are held by institutional investors. 70.4% of PACS Group shares are held by insiders. Comparatively, 0.8% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PACS Group | $5.29 billion | 0.96 | $191.54 million | $1.23 | 26.28 |
| Aclarion | $80,000.00 | 34.85 | -$7.23 million | ($17.01) | -0.19 |
PACS Group has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for PACS Group and Aclarion, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PACS Group | 0 | 1 | 4 | 1 | 3.00 |
| Aclarion | 1 | 0 | 0 | 0 | 1.00 |
PACS Group presently has a consensus price target of $44.40, indicating a potential upside of 37.35%. Given PACS Group’s stronger consensus rating and higher probable upside, equities analysts plainly believe PACS Group is more favorable than Aclarion.
Volatility and Risk
PACS Group has a beta of -0.64, indicating that its share price is 164% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
Summary
PACS Group beats Aclarion on 12 of the 15 factors compared between the two stocks.
About PACS Group
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for PACS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PACS Group and related companies with MarketBeat.com's FREE daily email newsletter.
